Trial Profile
Stelara® and Tremfya® Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary) ; Ustekinumab (Primary)
- Indications Atopic dermatitis; Crohn's disease; Psoriatic arthritis
- Focus Adverse reactions
- 10 Dec 2019 Planned number of patients changed from 100 to 200.
- 10 Dec 2019 Status changed from active, no longer recruiting to recruiting.
- 10 Dec 2019 Planned End Date changed from 1 Jul 2022 to 1 Dec 2025.